98%
921
2 minutes
20
Background: D-dimer, a degradation product of cross-linked fibrin, is a marker for hypercoagulability and thrombotic events. Moderately elevated levels of D-dimer are associated with the risk of venous and arterial events in patients with vascular disease. We assessed the role of D-dimer levels in predicting long-term vascular outcomes, cause-specific mortality, and new cancers in the LIPID trial (Long-Term Intervention with Pravastatin in Ischaemic Disease) in the context of other risk factors.
Methods: LIPID randomized patients to placebo or pravastatin 40 mg/d 5 to 38 months after myocardial infarction or unstable angina. D-dimer levels were measured at baseline and at 1 year. Median follow-up was 6.0 years during the trial and 16 years in total.
Results: Baseline D-dimer levels for 7863 patients were grouped by quartile (≤112, 112-173, 173-273, >273 ng/mL). Higher levels were associated with older age, female sex, history of hypertension, poor renal function, and elevated levels of B-natriuretic peptide, high-sensitivity C-reactive protein, and sensitive troponin I (each P<0.001). During the first 6 years, after adjustment for up to 30 additional risk factors, higher D-dimer was associated with a significantly increased risk of a major coronary event (quartile 4 versus 1: hazard ratio [HR], 1.45; 95% confidence interval, 1.21-1.74), major cardiovascular disease (CVD) event (HR, 1.45; 95% confidence interval, 1.23-1.71) and venous thromboembolism (HR, 4.03; 95% confidence interval, 2.31-7.03; each P<0.001). During the 16 years overall, higher D-dimer was an independent predictor of all-cause mortality (HR, 1.59), CVD mortality (HR, 1.61), cancer mortality (HR, 1.54), and non-CVD noncancer mortality (HR, 1.57; each P<0.001), remaining significant for deaths resulting from each cause occurring beyond 10 years of follow-up (each P≤0.01). Higher D-dimer also independently predicted an increase in cancer incidence (HR, 1.16; P=0.02).The D-dimer level increased the net reclassification index for all-cause mortality by 4.0 and venous thromboembolism by 13.6.
Conclusions: D-dimer levels predict long-term risk of arterial and venous events, CVD mortality, and non-CVD noncancer mortality independent of other risk factors. D-dimer is also a significant predictor of cancer incidence and mortality. These results support an association of D-dimer with fatal events across multiple diseases and demonstrate that this link extends beyond 10 years' follow-up.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1161/CIRCULATIONAHA.117.029901 | DOI Listing |
Thromb Haemost
September 2025
Medical Intensive Care Unit, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
This study aimed to identify new sepsis subphenotypes on the basis of coagulation indicator trajectories and comprise clinical characteristics and prognosis.This retrospective study included patients diagnosed with sepsis admitted to the intensive care unit of Peking Union Medical College Hospital from May 2016 to March 2023. Using group-based trajectory models, we classified patients into different subphenotypes on the basis of the dynamic daily changes in coagulation parameters within the first 7 days after sepsis diagnosis.
View Article and Find Full Text PDFAnn Hematol
September 2025
Faculty of Medicine, Division of Hematology, Department of Internal Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey.
The development of pulmonary hypertension (PH) after splenectomy is one of the recently controversial issues. This study aims to investigate whether splenectomy itself is an independent risk factor for the development of PH or if the primary contributor to PH development is the underlying condition that necessitated splenectomy. This study was conducted prospectively.
View Article and Find Full Text PDFBackground: This study aimed to evaluate the predictive value of combining the Padua score with D-dimer levels for identifying lower extremity deep vein thrombosis (DVT) in acute ischemic stroke (AIS) patients undergoing intravenous thrombolysis with alteplase.
Methods: This retrospective study analyzed clinical data from 632 AIS patients who received alteplase treatment at our hospital between September 2019 and October 2023. After applying strict inclusion and exclusion criteria, a total of 172 patients were included in the analysis: 35 patients in the DVT group and 137 patients in the non-DVT group.
Infect Drug Resist
September 2025
Department of Laboratory Medicine, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, 317000, People's Republic of China.
Purpose: Sepsis has high mortality and progresses rapidly, requiring early diagnosis; traditional scoring and lab parameters are limited in non-ICU settings, highlighting the need for biomarker integration and continuous monitoring to enhance diagnostic accuracy.
Patients And Methods: A retrospective analysis of 1,098 patients at Taizhou Hospital of Zhejiang Province identified sepsis and non-sepsis groups per Sepsis 3.0 criteria, Logistic regression analyses were used to identify the risk factors.
Acta Neurol Belg
September 2025
Department of Neurology, Bursa Yuksek Ihtisas Training and Research Hospital, Bursa, Turkey.
Objective: This study aimed to retrospectively evaluate the prevalence of COVID-19 infection among patients with Parkinson's disease (PD), along with the clinical course and factors associated with mortality.
Methods: A total of 1,786 patients diagnosed with Parkinson's disease and registered at our hospital were screened. Among these, 222 had undergone PCR testing for COVID-19, of whom 76 tested negative and 152 tested positive, indicating a COVID-19 prevalence of 8.